和誉-B(02256)：FGFR4抑制剂依帕戈替尼完成全球I期研究扩展阶段美国首例患者给药

Core Viewpoint - The company announced that its subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd., has successfully completed the first patient dosing in a global multicenter Phase I clinical study of its self-developed selective small molecule FGFR4 inhibitor, Irpagratinib (ABSK-011), targeting FGF19 overexpressing advanced hepatocellular carcinoma (HCC) [1] Group 1 - The Phase I clinical study (ABSK-011-101) is focused on advanced hepatocellular carcinoma (HCC) [1] - Irpagratinib has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), which is expected to accelerate its global clinical development process [1]